ABG WTT Global Life Science Capital Partners GP Ltd Invests $28.16 Million in CeriBell (NASDAQ:CBLL)

ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,088,101 shares of the company's stock, valued at approximately $28,160,000. CeriBell makes up about 64.4% of ABG WTT Global Life Science Capital Partners GP Ltd's investment portfolio, making the stock its largest holding. ABG WTT Global Life Science Capital Partners GP Ltd owned about 3.04% of CeriBell at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CBLL. Legal & General Group Plc acquired a new stake in CeriBell during the fourth quarter worth $32,000. Summit Investment Advisors Inc. acquired a new position in CeriBell during the 4th quarter worth approximately $33,000. Tower Research Capital LLC TRC purchased a new position in CeriBell in the fourth quarter valued at $37,000. PNC Financial Services Group Inc. acquired a new position in CeriBell in the fourth quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. purchased a new position in shares of CeriBell in the 4th quarter valued at $158,000.

Insiders Place Their Bets

In related news, CEO Xingjuan Chao sold 5,700 shares of the stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the transaction, the chief executive officer now directly owns 746,451 shares in the company, valued at $11,211,694.02. This represents a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 24,700 shares of company stock valued at $372,434.

Analyst Ratings Changes

CBLL has been the topic of a number of recent research reports. LADENBURG THALM/SH SH began coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price on the stock. Canaccord Genuity Group restated a "buy" rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Stock Up 1.2 %

Shares of NASDAQ:CBLL opened at $16.28 on Friday. The stock's fifty day moving average price is $19.03. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. Analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell (NASDAQ:CBLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.